NCT05836857 2026-04-16
The Use of Cannabis (Marijuana) and Cannabidiol (CBD) Among Cancer Patients: A Pilot Study
M.D. Anderson Cancer Center
Active not recruiting
Clinical Trials
23 trialsNCT07459920 2026-03-10
CAPTURE
National Cancer Institute, Naples
Phase 2 Not yet recruiting
NCT05629702 2026-01-30
ARISTOCRAT
University of Birmingham
Phase 2 Recruiting
NCT04827992 2025-11-05
Evaluation of Medical Cannabis and Prescription Opioid Taper Support for Reduction of Pain and Opioid Dose in Patients With Chronic Non-Cancer Pain
Massachusetts General Hospital
Phase NA Completed
NCT03948074 2025-09-10
CAFCARS
British Columbia Cancer Agency
Phase 2 Completed
NCT05969314 2025-04-11
To Check Safety of Ayurvedic Oral Cannabis in Breast and Head and Neck Cancer
Tata Memorial Hospital
Phase 1 Active not recruiting
NCT05663346 2025-02-14
Cannabis and Cancer, an Online Training for Oncology Nurses
Ciusss de L'Est de l'Île de Montréal
Phase NA Completed
NCT03245658 2023-12-18
The Effect of Cannabis in Pancreatic Cancer
University of Copenhagen
Phase 2 Withdrawn
NCT00674609 2023-05-03
SPRAY
Jazz Pharmaceuticals
Phase 3 Completed
NCT00675948 2023-05-03
Study to Compare the Safety and Tolerability of Sativex® in Patients With Cancer Related Pain
Jazz Pharmaceuticals
Phase 3 Completed
NCT01337089 2023-04-12
Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
Jazz Pharmaceuticals
Phase 3 Completed
NCT01361607 2023-04-12
SPRAY III
Jazz Pharmaceuticals
Phase 3 Completed
NCT01424566 2023-04-12
A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer
Jazz Pharmaceuticals
Phase 3 Completed
NCT01812603 2022-12-20
A Safety Study of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma
Jazz Pharmaceuticals
Phase 1/2 Completed
NCT01812616 2022-12-20
A Safety Study of Sativex Compared With Placebo (Both With Dose-intense Temozolomide) in Recurrent Glioblastoma Patients
Jazz Pharmaceuticals
Phase 1/2 Completed
NCT02073474 2022-12-20
An Observational Post-Marketing Safety Registry of Sativex®
Jazz Pharmaceuticals
Completed
NCT03522467 2019-09-25
COPE
Aurora Cannabis Inc
Phase 2 Unknown
NCT03246113 2019-08-13
Tolerability of Cannabis in Patients Receiving Concurrent Chemoradiation for Glioblastoma
New York State Psychiatric Institute
Phase 1 Terminated
NCT01262651 2018-04-23
Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer
GWPharm
Phase 3 Completed
NCT01983267 2017-05-08
Evaluation Prospectively the Level of Reduction in Cognitive Functions of Cancer Patients Who Are on Active Oncology Treatments and Use Cannabis. The Second Goal is to Identify High-risk Groups for Cognitive Impairment Due to Cannabis Use.
Rambam Health Care Campus
Phase NA Completed
NCT01975688 2016-08-11
A Pharmacokinetic Study of Single Doses of Sativex in Treatment-induced Mucositis
GWPharm
Phase 1 Terminated
NCT02432612 2016-03-02
A Study to Assess the Pharmacokinetic (PK) Properties of Sativex® in Patients With Advanced Cancer
GWPharm
Phase 1 Withdrawn
NCT00530764 2013-06-20
SPRAY
GWPharm
Phase 2 Completed